The Board of Directors of the Company at its meeting held today August 12 2021 has inter alia considered and approved the Scheme of Amalgamation (Scheme) pursuant to sections 230-232 and other applicable provisions of the Companies Act 2013 providing for the amalgamation of its wholly owned subsidiaries viz. Auronext Pharma Private Limited and Mviyes Pharma Ventures Private Limited (Transferor Companies) with Aurobindo Pharma Limited (Transferee Company).
The Scheme would be subject to the requisite statutory / regulatory approvals including the approval of the National Company Law Tribunal (Hyderabad Bench).
We enclose herewith the details as required under SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 read with SEBI Circular No.CIR/CFD/CMD/4/2015 dated September 9 2015 in Annexure-A to this letter.
Ask Value Research 
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
